PAM Stock Recent News

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.

OPRA, PAM, and SIRI made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 30, 2024.

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.

PAM, UI and BPRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 19, 2024.

CRNC, PAM and MHO made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 19, 2024.

Pampa (PAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Does Pampa Energia (PAM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.